MA40094B1 - Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation - Google Patents

Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Info

Publication number
MA40094B1
MA40094B1 MA40094A MA40094A MA40094B1 MA 40094 B1 MA40094 B1 MA 40094B1 MA 40094 A MA40094 A MA 40094A MA 40094 A MA40094 A MA 40094A MA 40094 B1 MA40094 B1 MA 40094B1
Authority
MA
Morocco
Prior art keywords
interleukin
polypeptide
methods
fusion proteins
fusion protein
Prior art date
Application number
MA40094A
Other languages
English (en)
French (fr)
Other versions
MA40094A1 (fr
Inventor
Thomas Malek
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40094(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Miami filed Critical Univ Miami
Publication of MA40094A1 publication Critical patent/MA40094A1/fr
Publication of MA40094B1 publication Critical patent/MA40094B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
MA40094A 2014-08-06 2015-08-04 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation MA40094B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
PCT/US2015/043792 WO2016022671A1 (en) 2014-08-06 2015-08-05 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Publications (2)

Publication Number Publication Date
MA40094A1 MA40094A1 (fr) 2021-09-30
MA40094B1 true MA40094B1 (fr) 2022-05-31

Family

ID=53836871

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40094A MA40094B1 (fr) 2014-08-06 2015-08-04 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
MA40721A MA40721B1 (fr) 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA40721A MA40721B1 (fr) 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Country Status (32)

Country Link
US (3) US12084483B2 (https=)
EP (2) EP4438621A3 (https=)
JP (3) JP6723982B2 (https=)
KR (1) KR102653758B1 (https=)
CN (2) CN107074967B (https=)
AU (3) AU2015301071C1 (https=)
BR (1) BR112017001940A2 (https=)
CA (1) CA2957273C (https=)
CL (1) CL2017000284A1 (https=)
CO (1) CO2017002166A2 (https=)
DK (1) DK3177307T3 (https=)
EA (2) EA035956B1 (https=)
ES (1) ES2986097T3 (https=)
FI (1) FI3177307T3 (https=)
HR (1) HRP20241258T1 (https=)
HU (1) HUE068478T2 (https=)
IL (2) IL250007B (https=)
LT (1) LT3177307T (https=)
MA (2) MA40094B1 (https=)
MX (1) MX388977B (https=)
MY (1) MY180831A (https=)
PE (1) PE20170503A1 (https=)
PH (1) PH12017500042A1 (https=)
PT (1) PT3177307T (https=)
RS (1) RS65930B1 (https=)
SA (1) SA517380842B1 (https=)
SG (2) SG10201913695PA (https=)
SI (1) SI3177307T1 (https=)
SM (1) SMT202400414T1 (https=)
TN (1) TN2017000020A1 (https=)
WO (1) WO2016022671A1 (https=)
ZA (1) ZA201700245B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
KR102042246B1 (ko) 2014-02-06 2019-11-28 에프. 호프만-라 로슈 아게 인터류킨-2 융합 단백질 및 이의 용도
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP3458485B1 (en) * 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CA3084262A1 (en) * 2017-12-06 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019183389A1 (en) * 2018-03-23 2019-09-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
JP7464530B2 (ja) * 2018-03-28 2024-04-09 ブリストル－マイヤーズ スクイブ カンパニー インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法
EP3941935A1 (en) 2019-03-18 2022-01-26 Biontech Cell & Gene Therapies Gmbh Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
JP2022533254A (ja) * 2019-05-24 2022-07-21 プロヴィヴァ セラピューティクス （ホン コン） リミテッド Ｉｌ－２組成物およびその使用方法
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
CA3146156A1 (en) * 2019-07-12 2021-01-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
MX2022000991A (es) * 2019-07-25 2022-05-24 Univ Chicago Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
US20220378933A1 (en) * 2019-09-19 2022-12-01 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
MX2022004577A (es) * 2019-10-18 2022-05-10 Alkermes Pharma Ireland Ltd Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune.
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US11597753B2 (en) 2020-04-30 2023-03-07 Immune Targeting, Inc. Activatable IL2 composition and methods of use
KR20230050389A (ko) * 2020-08-13 2023-04-14 브리스톨-마이어스 스큅 컴퍼니 Il-2를 관심 표적 세포로 재지시하는 방법
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
CN118891055A (zh) * 2022-02-11 2024-11-01 穆拉肿瘤公司 用于癌症免疫疗法的组合物和方法
WO2023159135A2 (en) * 2022-02-16 2023-08-24 University Of Miami Il-2 and tl1a fusion proteins and methods of use thereof
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
EP4669671A1 (en) * 2023-02-22 2025-12-31 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ANTI-IL2RA ANTIBODIES AND THEIR USES
WO2025207491A1 (en) * 2024-03-25 2025-10-02 Mural Oncology, Inc. Compositions and methods for cancer immunotherapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE69530107T2 (de) 1994-12-28 2003-10-16 University Of Kentucky, Lexington Monoklonaler anti-idiotypischer antikörper 3h1 aus maus
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
JPWO2003029475A1 (ja) 2001-09-28 2005-01-20 株式会社ディナベック研究所 エピトープ結合β２ｍをコードする哺乳動物細胞感染性ウイルスベクターおよびその利用
BRPI0508470A (pt) 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
EP3263581B2 (en) * 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
CN101255197B (zh) 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP2553101A4 (en) 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
WO2012088383A2 (en) 2010-12-23 2012-06-28 Genentech, Inc. PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME
RS61391B1 (sr) * 2012-06-08 2021-02-26 Alkermes Pharma Ireland Ltd Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
EP4438621A2 (en) 2024-10-02
SA517380842B1 (ar) 2021-12-26
SI3177307T1 (sl) 2024-09-30
EP3177307B1 (en) 2024-07-17
JP6723982B2 (ja) 2020-07-15
AU2022204034A1 (en) 2022-07-14
KR20170030646A (ko) 2017-03-17
LT3177307T (lt) 2024-08-12
EA035956B1 (ru) 2020-09-04
NZ766851A (en) 2024-07-26
MX2017001062A (es) 2017-07-14
AU2015301071B2 (en) 2020-03-05
DK3177307T3 (da) 2024-10-07
US20170233448A1 (en) 2017-08-17
AU2015301071C1 (en) 2020-07-02
PT3177307T (pt) 2024-09-13
US20250163118A1 (en) 2025-05-22
EA202091342A2 (ru) 2020-11-30
BR112017001940A2 (pt) 2017-11-28
ZA201700245B (en) 2024-06-26
AU2015301071A1 (en) 2017-02-02
SG11201700706WA (en) 2017-02-27
AU2020203352B2 (en) 2022-03-10
AU2020203352A1 (en) 2020-07-02
EA202091342A3 (ru) 2020-12-30
TN2017000020A1 (en) 2018-07-04
IL250007B (en) 2020-07-30
MA40721A (fr) 2017-06-13
CA2957273C (en) 2023-03-14
EA201790063A1 (ru) 2017-06-30
JP7272663B2 (ja) 2023-05-12
WO2016022671A1 (en) 2016-02-11
MX388977B (es) 2025-03-20
IL275944B (en) 2022-02-01
NZ728042A (en) 2024-07-26
KR102653758B1 (ko) 2024-04-04
MY180831A (en) 2020-12-10
MA40094A1 (fr) 2021-09-30
JP2023099045A (ja) 2023-07-11
FI3177307T3 (fi) 2024-10-04
CL2017000284A1 (es) 2017-11-17
MA40721B1 (fr) 2024-08-30
HRP20241258T1 (hr) 2024-12-06
IL275944A (en) 2020-08-31
SG10201913695PA (en) 2020-03-30
PH12017500042A1 (en) 2017-05-22
CN113912737A (zh) 2022-01-11
CA2957273A1 (en) 2016-02-11
CO2017002166A2 (es) 2017-05-19
HUE068478T2 (hu) 2025-01-28
IL250007A0 (en) 2017-03-30
JP2021000084A (ja) 2021-01-07
CN107074967A (zh) 2017-08-18
US12084483B2 (en) 2024-09-10
CN107074967B (zh) 2021-06-08
JP2017523789A (ja) 2017-08-24
US20230079120A1 (en) 2023-03-16
ES2986097T3 (es) 2024-11-08
EP4438621A3 (en) 2024-12-18
EP3177307A1 (en) 2017-06-14
RS65930B1 (sr) 2024-10-31
SMT202400414T1 (it) 2024-11-15
PE20170503A1 (es) 2017-05-11

Similar Documents

Publication Publication Date Title
MA40094B1 (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
WO2020142625A3 (en) Compositions for increasing half-life of a therapeutic agent in canines and methods of use
SA521422459B1 (ar) مثبطات غير قابلة للانعكاس لتفاعل المينين - mll
MY205933A (en) Sirp-alpha binding proteins and methods of use thereof
MA46814B2 (fr) Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
MX2021010531A (es) Proteina de fusion bifuncional y uso farmaceutico de la misma.
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA40801B2 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MY199278A (en) Anti-b7-h3 antibodies and antibody drug conjugates
EA201891656A1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки для лечения аутоиммунных заболеваний
MX386014B (es) Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
BR112022001575A2 (pt) Formulações de anticorpos anti-pvrig e usos dos mesmos
MA43817B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
BR112018075649A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
MA43457A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
WO2016014428A3 (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3980035A4 (en) FOXP-ENGINEERED CD4+ T-CELLS FOR USE IN TREG-BASED IMMUNOTHERAPY
MX2021007479A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
MX2020007628A (es) Composiciones y metodos de uso.
WO2020247388A3 (en) Il-2alpha receptor subunit binding compounds
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
WO2019090215A3 (en) Dominant negative ligand chimeric antigen receptor systems
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
MA48751B1 (fr) Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax
MX2020011814A (es) Anticuerpo anti-tlr7 humano.